167 related articles for article (PubMed ID: 25122505)
21. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
22. 1, 6-di-O-caffeoyl-β-D-glucopyranoside, a natural compound from Callicarpa nudiflora Hook impairs P2Y
Fu J; Zhu X; Wang W; Lu H; Zhang Z; Liu T; Xu H; Fu H; Ma S; Luo Y
Phytomedicine; 2017 Dec; 36():273-282. PubMed ID: 29157825
[TBL] [Abstract][Full Text] [Related]
23. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
Liao CH; Ko FN; Wu CL; Teng CM
J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.
Bleasdale JE; Thakur NR; Gremban RS; Bundy GL; Fitzpatrick FA; Smith RJ; Bunting S
J Pharmacol Exp Ther; 1990 Nov; 255(2):756-68. PubMed ID: 2147038
[TBL] [Abstract][Full Text] [Related]
25. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
26. Antiplatelet action of indirubin-3'-monoxime through suppression of glycoprotein VI-mediated signal transduction: a possible role for ERK signaling in platelets.
Lee JJ; Han JH; Jung SH; Lee SG; Kim IS; Cuong NM; Huong TT; Khanh PN; Kim YH; Yun YP; Ma JY; Myung CS
Vascul Pharmacol; 2014 Dec; 63(3):182-92. PubMed ID: 25451564
[TBL] [Abstract][Full Text] [Related]
27. Src family kinase-mediated and Erk-mediated thromboxane A2 generation are essential for VWF/GPIb-induced fibrinogen receptor activation in human platelets.
Garcia A; Quinton TM; Dorsam RT; Kunapuli SP
Blood; 2005 Nov; 106(10):3410-4. PubMed ID: 16020504
[TBL] [Abstract][Full Text] [Related]
28. Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity.
Hirakata H; Ushikubi F; Toda H; Nakamura K; Sai S; Urabe N; Hatano Y; Narumiya S; Mori K
Anesthesiology; 1996 Dec; 85(6):1447-53. PubMed ID: 8968193
[TBL] [Abstract][Full Text] [Related]
29. The mechanism of action of KBT-3022, a new antiplatelet agent.
Matsuo K; Yokota K; Yamashita A; Oda M
Gen Pharmacol; 1997 Feb; 28(2):229-35. PubMed ID: 9013200
[TBL] [Abstract][Full Text] [Related]
30. Piperine inhibits the activities of platelet cytosolic phospholipase A2 and thromboxane A2 synthase without affecting cyclooxygenase-1 activity: different mechanisms of action are involved in the inhibition of platelet aggregation and macrophage inflammatory response.
Son DJ; Akiba S; Hong JT; Yun YP; Hwang SY; Park YH; Lee SE
Nutrients; 2014 Aug; 6(8):3336-52. PubMed ID: 25153972
[TBL] [Abstract][Full Text] [Related]
31. KRDS, a peptide derived from human lactotransferrin, inhibits thrombin-induced thromboxane synthesis by a cyclooxygenase-independent mechanism.
Lévy-Toledano S; Grelac F; Caen JP; Maclouf J
Thromb Haemost; 1995 May; 73(5):857-61. PubMed ID: 7482416
[TBL] [Abstract][Full Text] [Related]
32. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
Ogawa T; Sugidachi A; Asai F; Koike H
Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
[TBL] [Abstract][Full Text] [Related]
33. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production.
Cattaneo M; Tenconi PM; Lecchi A; Mannucci PM
Thromb Res; 1991 Jun; 62(6):717-24. PubMed ID: 1926062
[TBL] [Abstract][Full Text] [Related]
34. Platelet desensitization by arachidonic acid is associated with the suppression of endoperoxide/thromboxane A2 binding to the membrane receptor.
Sato T; Hashizume T; Nakao K; Akiba S; Fujii T
Biochim Biophys Acta; 1989 Aug; 992(2):168-73. PubMed ID: 2503041
[TBL] [Abstract][Full Text] [Related]
35. ALOX12 mutation in a family with dominantly inherited bleeding diathesis.
Mitsui T; Makino S; Tamiya G; Sato H; Kawakami Y; Takahashi Y; Meguro T; Izumino H; Sudo Y; Norota I; Ishii K; Hayasaka K
J Hum Genet; 2021 Aug; 66(8):753-759. PubMed ID: 33564083
[TBL] [Abstract][Full Text] [Related]
36. Antiplatelet Activity of a Newly Synthesized Novel Ruthenium (II): A Potential Role for Akt/JNK Signaling.
Khamrang T; Hung KC; Hsia CH; Hsieh CY; Velusamy M; Jayakumar T; Sheu JR
Int J Mol Sci; 2017 Apr; 18(5):. PubMed ID: 28448438
[TBL] [Abstract][Full Text] [Related]
37. αB-crystallin reduces ristocetin‑induced soluble CD40 ligand release in human platelets: suppression of thromboxane A2 generation.
Tsujimoto M; Doi T; Kuroyanagi G; Yamamoto N; Matsushima-Nishiwaki R; Iida Y; Enomoto Y; Iida H; Ogura S; Otsuka T; Tokuda H; Kozawa O; Iwama T
Mol Med Rep; 2015 Jul; 12(1):357-62. PubMed ID: 25760062
[TBL] [Abstract][Full Text] [Related]
38. Activation of rabbit platelets by Ca2+ influx and thromboxane A2 release in an external Ca(2+)-dependent manner by zooxanthellatoxin-A, a novel polyol.
Rho MC; Nakahata N; Nakamura H; Murai A; Ohizumi Y
Br J Pharmacol; 1995 Jun; 115(3):433-40. PubMed ID: 7582454
[TBL] [Abstract][Full Text] [Related]
39. Defective platelet response to arachidonic acid and thromboxane A(2) in subjects with Pl(A2) polymorphism of beta(3) subunit (glycoprotein IIIa).
Andrioli G; Minuz P; Solero P; Pincelli S; Ortolani R; Lussignoli S; Bellavite P
Br J Haematol; 2000 Sep; 110(4):911-8. PubMed ID: 11054082
[TBL] [Abstract][Full Text] [Related]
40. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
Li P; Ferrario CM; Brosnihan KB
J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
